inclusion criteria: 1. provision of signed and dated informed consent form from a participant or legally authorized representative (lar); 2. male or female, \>18 years old; 3. hospitalized participants with a laboratory diagnosis of covid-19 infection 4. evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines (table 3); 5. willing to adhere to the study intervention regimen;

inclusion criteria: 1. provision of signed and dated informed consent form from a participant or legally authorized representative (lar); 2. male or female, \>18 years old; 3. hospitalized participants with a laboratory diagnosis of covid-19 infection 4. evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines (table 3); 5. willing to adhere to the study intervention regimen;

inclusion criteria: provision of signed and dated informed consent form from a participant or legally authorized representative (lar); male or female, >18 years old; hospitalized participants with a laboratory diagnosis of covid-19 infection evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines (table 3); willing to adhere to the study intervention regimen;

inclusion criteria: provision of signed and dated informed consent form from a participant or legally authorized representative (lar); male or female, >18 years old; hospitalized participants with a laboratory diagnosis of covid-19 infection evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines (table 3); willing to adhere to the study intervention regimen;

inclusion criteria: 1. provision of signed and dated informed consent form from a participant or legally authorized representative (lar); 2. male or female, >18 years old; 3. hospitalized participants with a laboratory diagnosis of covid-19 infection 4. evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines (table 3); 5. willing to adhere to the study intervention regimen;

inclusion criteria: 1. provision of signed and dated informed consent form from a participant or legally authorized representative (lar); 2. male or female, >18 years old; 3. hospitalized participants with a laboratory diagnosis of covid-19 infection 4. evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines (table 3); 5. willing to adhere to the study intervention regimen;

inclusion criteria: 1. provision of signed and dated informed consent form from a participant or legally authorized representative (lar); 2. male or female, >18 years old; 3. admitted to hospital with a laboratory diagnosis of covid-19 infection and covid-19 related illness and evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines during the first 10 days following admission (table 3); 4. willing to adhere to the study intervention regimen;

inclusion criteria: 1. provision of signed and dated informed consent form from a participant or legally authorized representative (lar); 2. male or female, >18 years old; 3. admitted to hospital with a laboratory diagnosis of covid-19 infection and covid-19 related illness and evidence of persistent aki as defined by the kidney disease: improving global outcomes (kdigo) guidelines during the first 10 days following admission (table 3); 4. willing to adhere to the study intervention regimen;